An observational study in Myocardial Infarction, sponsored by AstraZeneca. Completed at 56 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-08.
Sponsored by AstraZeneca · Observational
The main objective of this case-referent study is to assess the impact of statins usage on the risk of having a first myocardial infarction (MI) in a real life situation in France
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 13,171 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Cases : Patients recruited by a cardiologist in hospital / Referents : Patients recruited by a GP, community sample
Exclusion Criteria:
Cases : Patients with a first myocardial infarction
Referents : Patients recruited by a GP during a routine consultation
Assess the impact of the different statins (molecules) usage on the risk of having a first myocardial infarction in a real life situation in France
Time frame: in 2011
Assess the interaction between statin treatment and risk factors such as cholesterol, age, gender, tobacco, alcohol, co-prescriptions, co-morbidities
Time frame: in 2011
Assess the populational impact of statins usage on the risk of having a first myocardial infarction
Time frame: in 2011
Assess the risk of having a first myocardial infarction according to high and low dosages of statins
Time frame: in 2011
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca